Program | CEC Workshop Warsaw 2025

Day ONE | 10.10.2025
Day TWO – WORKSHOPS | 11.10.2025

13:00 – 14:30

Arrival and Lunch

14:30 - 14:40

Welcome to the meeting: GILEAD

14:40 - 14:50

Introduction to the meeting: dr hab. n. med. Barbara Radecka, prof. UO, prof. dr hab.n.med. Tomasz Kubiatowski

14:50 - 16:30

SESSION I: BC - Treatment landscape from different perspectives
Co-chairs: prof. MUDr. Petra Tesařová, CSc., prof. dr hab. n. med. Ewa Kalinka

14:50-15:05

Epidemiology of breast cancer - prof. dr hab. n. med. Joanna Didkowska

15:05-15:20

TNBC treatment landscape in 2025 - MUDr. Miloš Holánek, Ph.D.

15:20-15:35

HR+/HER2 mBC treatment landscape in 2025 - doc. MUDr. Zuzana Bielčiková, PhD.

15:35-15:50

Breast cancer in young women - dr n. med. Joanna Kufel-Grabowska

15:50-16:05

Breast cancer in the elderly: A synergy between oncologist and geriatrician in improving patient outcomes? – dr n. med. Katarzyna Broczek

16:05-16:30

Panelists discussion:
Co-chairs: prof. MUDr. Petra Tesařová, CSc., prof. dr hab.n.med. Ewa Kalinka
PL: prof. dr hab. n. med. Elżbieta Senkus
PL: prof. dr hab. n. med. Joanna Didkowska
SK: MUDr. Branislav Bystrický, Ph.D., MPH
CZ: doc. MUDr. Zuzana Bielčiková, PhD.
PL: dr n. med. Joanna Kufel-Grabowska
PL: dr n. med. Katarzyna Broczek
CZ: doc. MUDr. Kateřina Kopečková, Ph.D

16:30-16:50

Coffe break

16:50-18:10

SESSION II: Registration studies of Sacituzumab govitecan : ASCENT and TROPiCS-02 – TRIALS VS. REALITY
Co-chairs: dr hab. n. med. Barbara Radecka, prof. UO, MUDr. Lucie Reifová

16:50-17:05

Sacituzumab govitecan in the treatment algorithm of mTNBC patients - dr n. med. Aleksandra Konieczna

17:05-17:20

Sacituzumab govitecan in the treatment algorithm of HR+/HER2- mBC patients - MUDr. Miloš Holánek, Ph.D.

17:20-17:35

Management of AE related to Sacituzumab govitecan treatment - MUDr. Filip Kohútek, Ph.D

17:35-17:50

Subgroup analysis (ASCENT and TROPiCS-02) - dr hab. n. med. Barbara Radecka, prof. UO

17:50-18:10

Panelists discussion:
Co-chairs: dr hab. n. med. Barbara Radecka, prof. UO, MUDr. Lucie Reifová
CZ: MUDr. Miloš Holánek, Ph.D.
SK: MUDr. Filip Kohútek, Ph.D.
CZ: Doc. MUDr. Kateřina Kopečková, Ph.D.
SK: MUDr. Branislav Bystrický, Ph.D., MPH
PL: dr n. med. Aleksandra Konieczna

18:10-18:25

Coffee break

18:25-19:15

SESSION III: Immunotherapy in BC treatment
Co-chairs: PL: prof. dr. hab. n. med. Tomasz Kubiatowski, doc. MUDr. Kateřina Kopečková, Ph.D.

18:25-18:40

Rationale for association of anti-TROP conjugated antibody with immunotherapy, hormone therapy - prof. dr. hab. n. med. Tomasz Kubiatowski

18:40-18:55

Sacituzumab govitecan in patients after immunotherapy treatment - prof. dr. hab. n. med. Ewa Kalinka

18:55-19:15

Panelists discussion:
Co-chairs: PL: prof. dr. hab. n. med. Tomasz Kubiatowski, doc. MUDr. Kateřina Kopečková, Ph.D
PL: prof. dr. hab. n. med. Tomasz Kubiatowski
PL: prof. dr. hab. n. med. Ewa Kalinka
CZ: doc. MUDr. Zuzana Bielčiková, PhD.
CZ: doc. MUDr. Kateřina Kopečková, Ph.D

End of the 1st day of the meeting

20:00

Dinner

9:00 - 09:30

SESSION IV: Randomized clinical trials versus real world evidence - what distinguishes the two areas of data acquisition:
9:00-9:15 dr hab. n. med. Mirosława Püsküllüoğlu from PL perspective
9:15-9:30 doc. MD Zuzana Bielčiková, PhD. from CZ perspective

WORKSHOPS

9:30- 9:40

Discussion of the purpose of the workshop work, introduction of Team chairs and assignment of workshop participants to individual groups – dr hab. n. med. Michał Jarząb

9:40-10:40

Different perspectives from clinicians from PL, CZ, SK in terms of individual aspects:
Group I - AEs management
Co-chairs: dr n. med. Małgorzata Pieniążek and MUDr. Branislav Bystrický, Ph.D., MPH

Group II - change in tumor biology/analysis of biomarkers/status of HER2
Co-chairs: dr n. med. Katarzyna Pogoda and MUDr. Lucie Reifová

Group III - elderly patients
Co-chairs: dr n. med. Aleksandra Konieczna and doc. MUDr. Zuzana Bielčiková, PhD.

Group IV - CNS metastases
Co-chairs: dr n. med. Marcin Kubeczko and doc. MUDr. Kateřina Kopečková, Ph.D.

10:40-10:55

Coffee break

10:55-11:35

Summary of conclusions from workshops by the co-chairs/chair of the various groups
Chair: dr hab. n. med. Michał Jarząb
Group 1 - 10 min
Group 2 - 10 min
Group 3 - 10 min
Group 4 - 10 min
Summary of workshops 10 min: dr hab. n. med.Michał Jarząb

11:35-11:50

Coffee break

11:50-13:00

SESSION V: Patient cases study
Chairs: PL , doc. MD Zuzana Bielčiková, PhD.

11:50-12:00

Case study mTNBC - MUDr. Filip Kohútek, Ph.D

12:00-12:10

Case study HR+/ HER2- mBC - dr. Milos Holanek, Ph.D.

12:10-12:20

Case study mTNBC - lek.med. Małgorzata Podskarbi

12:20-12:30

Case study HR+/HER2- mBC - dr n. med. Anna Polakiewicz-Gilowska

12:30-13:00

Summary: PL and doc. MD Zuzana Bielčiková, PhD.

13:00-13:45

SESSION VI: Organization of the oncology Breast Cancer care in PL, CZ and SK
Co-chairs: prof. dr hab. n. med. Elżbieta Senkus , MUDr. Branislav Bystrický, Ph.D., MPH

13:00-13:10

The Polish perspective - dr n. med. Katarzyna Pogoda

13:10-13:20

The Czech Republic perspective - prof. MUDr. Petra Tesařová, CSc.

13:20-13:30

The Slovak perspective - MUDr. Branislav Bystrický, Ph.D., MPH

13:30–13:45

Co-chairs discussion: prof. dr hab.n.med. Elżbieta Senkus, MUDr. Branislav Bystrický, Ph.D., MPH

PL: dr n.med. Katarzyna Pogoda
CZ: prof. MUDr. Petra Tesařová, CSc.
SK: MUDr. Branislav Bystrický, Ph.D., MPH

13:45-14:00

Summary of the conference and formulation of theses of the final position paper
prof. dr hab. n. med. Tomasz Kubiatowski, dr hab. n. med. Barbara Radecka, prof. UO, prof. MUDr. Petra Tesařová, CSc., MUDr. Branislav Bystrický, Ph.D., MPH

14:00

Lunch and departures